Coffee protects against liver cancer while alcohol is linked with numerous cancers

Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin.

The study looked at data from 860 reviews (meta-analyses) of published studies, which explored the association between food and nutrient intake and the risk of either developing or dying from 11 different cancers. According to NHS Digital(2), 65% of men and 50% of women in the UK had drunk alcohol in the last week. When alcohol is metabolized, it breaks down into chemicals which can bind to DNA, resulting in mutations which could become cancerous. Alcohol can also increase the levels of the hormones linked to the development of some types of breast cancer.

Coffee is one of the most commonly consumed beverages at a global level and it is thought that the beneficial effects of coffee consumption might be due to the antioxidant and anti-inflammatory properties that may protect against diseases triggered by inflammation like cancer.

Dr Giota Mitrou, Director of Research and Innovation, WCRF said: "This umbrella review confirms the evidence we have for alcohol and coffee in relation to cancer. Further research needs to better understand the mechanisms involved in the links between coffee and cancer as well as between alcohol and different cancer subtypes. As always, we continue to encourage limiting alcohol intake as part of our Cancer Prevention Recommendations which include being a healthy weight, being physically active and enjoying a diet rich in wholegrains, vegetables, fruit and pulses."

The authors of the study are calling for more targeted public health policies in order to deter the known major diet related risk factors for cancer, particularly alcohol consumption.

This study was funded by WCRF, and was led by Dr Kostas Tsilidis, Senior Lecturer in Cancer Epidemiology in the Department of Epidemiology and Biostatistics of Imperial College. This study is an umbrella review to systematically evaluate the robustness of the observational meta-analytic evidence across a large number of associations with risk of cancer at 11 sites. They further evaluated whether additional research is or is not warranted to change the inferences from the existing meta-analyses using an adaptation of research synthesis methods.

The findings in this study confirms the evidence from the WCRF Third Expert Report, positively linking alcohol consumption with cancers of the mouth, pharynx, larynx, oesophageal (squamous cell carcinoma), breast, colorectal, stomach and liver cancer.

1. Papadimitriou, N., Markozannes, G., Kanellopoulou, A. et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun 12, 4579 (2021). https://doi.org/10.1038/s41467-021-24861-8
2. NHS Digital, Statistics on Alcohol, England 2020. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-alcohol/2020/part-4. Last accessed: August 2021

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...